Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia

Nägga, Katarina LU ; Gottfries, Johan ; Blennow, Kaj and Marcusson, Jan (2002) In Dementia and Geriatric Cognitive Disorders 14(4). p.183-190
Abstract
The two most frequently examined biomarkers in the diagnosis of dementia are cerebrospinal fluid (CSF) tau and beta-amyloid(1-42) (Abeta(1-42)). An assay for tau phosphorylated at threonine 181 (phospho-tau) has recently been developed. We studied these three markers in patients with possible Alzheimer's disease (AD; n = 23), probable AD (n = 50), AD with relevant cerebrovascular disease (AD with CVD; n = 14), possible vascular dementia (VaD; n = 39), probable VaD (n = 36), cognitively impaired (n = 13) and 27 neurologically healthy controls. Compared with the controls, tau levels were significantly increased in possible AD, probable AD, AD with CVD and probable VaD. Abeta(1-42) was decreased in all dementia groups compared with the... (More)
The two most frequently examined biomarkers in the diagnosis of dementia are cerebrospinal fluid (CSF) tau and beta-amyloid(1-42) (Abeta(1-42)). An assay for tau phosphorylated at threonine 181 (phospho-tau) has recently been developed. We studied these three markers in patients with possible Alzheimer's disease (AD; n = 23), probable AD (n = 50), AD with relevant cerebrovascular disease (AD with CVD; n = 14), possible vascular dementia (VaD; n = 39), probable VaD (n = 36), cognitively impaired (n = 13) and 27 neurologically healthy controls. Compared with the controls, tau levels were significantly increased in possible AD, probable AD, AD with CVD and probable VaD. Abeta(1-42) was decreased in all dementia groups compared with the controls. In contrast, phospho-tau levels were increased only in probable AD compared with the controls. From the results of the present study, it is concluded that neither measurement of phospho-tau, tau nor Abeta(1-42) in CSF can discriminate entirely between dementia and cognitively non-disturbed controls or between dementia of different aetiologies in the clinical diagnostic procedure. (Less)
Please use this url to cite or link to this publication:
author
; ; and
publishing date
type
Contribution to journal
publication status
published
subject
in
Dementia and Geriatric Cognitive Disorders
volume
14
issue
4
pages
183 - 190
publisher
Karger
external identifiers
  • wos:000179464900003
  • scopus:0036968010
ISSN
1420-8008
DOI
10.1159/000066023
language
English
LU publication?
no
id
d251df4a-8156-4788-b611-a19ef94dd4e8 (old id 1297542)
date added to LUP
2016-04-01 12:17:25
date last changed
2022-02-03 20:12:30
@article{d251df4a-8156-4788-b611-a19ef94dd4e8,
  abstract     = {{The two most frequently examined biomarkers in the diagnosis of dementia are cerebrospinal fluid (CSF) tau and beta-amyloid(1-42) (Abeta(1-42)). An assay for tau phosphorylated at threonine 181 (phospho-tau) has recently been developed. We studied these three markers in patients with possible Alzheimer's disease (AD; n = 23), probable AD (n = 50), AD with relevant cerebrovascular disease (AD with CVD; n = 14), possible vascular dementia (VaD; n = 39), probable VaD (n = 36), cognitively impaired (n = 13) and 27 neurologically healthy controls. Compared with the controls, tau levels were significantly increased in possible AD, probable AD, AD with CVD and probable VaD. Abeta(1-42) was decreased in all dementia groups compared with the controls. In contrast, phospho-tau levels were increased only in probable AD compared with the controls. From the results of the present study, it is concluded that neither measurement of phospho-tau, tau nor Abeta(1-42) in CSF can discriminate entirely between dementia and cognitively non-disturbed controls or between dementia of different aetiologies in the clinical diagnostic procedure.}},
  author       = {{Nägga, Katarina and Gottfries, Johan and Blennow, Kaj and Marcusson, Jan}},
  issn         = {{1420-8008}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{183--190}},
  publisher    = {{Karger}},
  series       = {{Dementia and Geriatric Cognitive Disorders}},
  title        = {{Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia}},
  url          = {{http://dx.doi.org/10.1159/000066023}},
  doi          = {{10.1159/000066023}},
  volume       = {{14}},
  year         = {{2002}},
}